Our development pipeline
DEVELOPMENT pipeline
Reinvesting our profit to discover new medicines
At Servier, we choose to reinvest our profit to discover new medicines. Our development pipeline offers a tangible reflection of this commitment. Over recent years, it has expanded to comprise 75 projects, 43 of which in development and 32 research projects.
This innovative pipeline currently offers considerable potential for the Group to differentiate itself and create value, with 50% of projects deemed to be first in class.
33 Clinical projects
16
Phase 1
6
Phase 2
6
Phase 3
5
Filling
Updated in January 2023
Oncology
SOLID TUMORS
Compound / MOA
Project
Therapeutic area
Phase
FTD/TPI combo bevacizumab
S95005
Solid tumors (new indication)
DPC
1
2
3
Futuximab / modotuximab
combo FTD/TPI
combo FTD/TPI
S95026
Solid tumors (new indication)
DPC
1
2
3
Vorasidenib
S95032
Low grade Glioma with IDH 1/2 mutation
DPC
1
2
3
Ivosidenib
S95031
Solid tumors (new indication)
DPC
1
2
3
Anti-MET
S95027
Non small Cell Lung Cancer
DPC
1
2
3
Vorasidenib + pembrolizumab
S95032
Grade 2-3 glioma with IDH1/2 mutation
DPC
1/2
3
Ivosidenib combo
S95031
Solid tumors (new indication)
DPC
1/2
3
Anti-TIM3 combo
S95018
Solid tumors
DPC
1/2
3
Anti-CD73
S95024
Solid tumors
DPC
1/2
3
Anti-PD-L1/4-1BB
S95012
Solid tumors
DPC
1/2
3
Anti-NKG2A
S95029
Solid tumors
DPC
1/2
3
Inhibiteur de MAT2A
S95035
Solid tumors
DPC
1
2
3
Anti-FLT3
S95040
Solid tumors
DPC
1
2
3
HEMATOLOGICAL MALIGNANCIES
Compound / MOA
Project
Therapeutic area
Phase
Ivosidenib + 7+3 (chimio)
S95031
Hematological malignancies (new indication)
DPC
1
2
3
UCART 19
S68587/S95023
Hematological malignancies
DPC
1
2
3
Calaspargase pegol
S95015
Hematological malignancies (new indication)
DPC
1
2
3
Pegaspargase
S95014
Hematological malignancies (new formulation)
DPC
1
2
3
Ivosidenib
S95031
Hematological malignancies (new indication)
DPC
1/2
3
BCL-2 inhibitor + Mcl1 inhibitor (S64315)
S65487
Acute Myeloid Leukemia
DPC
1/2
3
BCL-2 inhibitor + azacitidine
S65487
1st line Acute Myeloid Leukemia (AML)
DPC
1/2
3
Mcl1 inhibitor + azacitidine
S64315
Relapsed/Refractory Acute Myeloid Leukemia (AML)
DPC
1/2
3
Neuroscience
Compound / MOA
Project
Therapeutic area
Phase
LRRK2 inhibitor
S221237
Parkinson’s Disease
DPC
1
2
3
Immuno-inflammation
Compound / MOA
Project
Therapeutic area
Phase
Anti-IL7R
S95011
Sjögren syndrome
DPC
1
2
3
Anti-IL7R
S95011
Ulcerative colitis
DPC
1
2
3
PCD= Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3; FTD/TPI: trifluridine/ tipiracil; EGFR: epidermal growth factor receptor; IDH: Isocitrate dehydrogenase; AYA: Adolescents and Young Adults; MOA: Mode of Action